Considering that the oncogenic function of COL4A1 in HCC relies on FAK and Src activation, we wonder whether inhibiting FAK or Src activity is an effective approach to treat HCC patients with high expression of COL4A1. Here, SRC is linked to hepatocellular carcinoma.